A note on this column: This article is general medical information, not a description of a service offered at this practice. Dr. Ishiguro's surgical practice is focused on hip and knee conditions — he does not treat or perform surgery for trigger finger. This column is written to help readers understand a very common hand condition and know when and how to seek the right specialist, typically a hand surgeon or orthopaedic surgeon, or a physician for an initial evaluation.
What trigger finger actually is
Trigger finger, medically called stenosing tenosynovitis or "stenosing flexor tenosynovitis," occurs when a flexor tendon in the finger no longer glides smoothly through the tunnel formed by the A1 pulley — a fibrous band at the base of the finger, on the palm side, that holds the tendon close to the bone. A mismatch develops between the size of the tendon (often thickened, or with a nodule) and the space inside the pulley. As the tendon tries to slide through this narrowed passage, it catches, producing a painful click or pop with bending or straightening, and in more advanced cases the finger locks in a bent position and has to be straightened passively with the other hand.
Despite the "-itis" naming convention, tissue studies show relatively little classic inflammation. Instead, the pulley and the tendon sheath undergo a fibrocartilaginous change — thickening and stiffening of the connective tissue — while the tendon itself often develops a localised nodule just beneath the pulley. Any finger can be affected, but the ring finger and thumb are the most common sites, and more than one digit is affected in a meaningful proportion of patients, particularly those with diabetes.
Who gets it, and why
Trigger finger is common: population estimates generally place its prevalence at around 1–2% in the general population, rising substantially — commonly cited in the range of 5–20% — among people with diabetes mellitus. Several other associations are well established in the literature.
Established risk factors
- Diabetes mellitus — the most consistently identified medical risk factor, with risk rising further with longer diabetes duration
- Female sex — women are affected considerably more often than men across most series
- Age — incidence peaks in the 50s and 60s, though it can occur at any age, including in children (a distinct, less common paediatric form)
- Carpal tunnel syndrome and other repetitive hand-use conditions — frequently coexist, likely sharing overlapping mechanisms
- Hypothyroidism, obesity, and rheumatoid arthritis — each identified as an associated condition, though with weaker evidence than diabetes
What the evidence shows — diabetes as a risk factor: A Swedish longitudinal cohort study following more than 30,000 participants from the Malmö Diet and Cancer Study for over 20 years found that baseline diabetes mellitus was associated with an adjusted hazard ratio of 2.0 (95% CI 1.5–2.6) for later development of trigger finger, after adjustment for age, sex, and other confounders (Löfgren et al., Frontiers in Clinical Diabetes and Healthcare, 2021). This is one of the more robust pieces of evidence establishing diabetes as an independent risk factor rather than simply a coincidental association, and is a useful reminder to check blood glucose status in patients presenting with trigger finger, particularly when multiple digits are involved.
Symptoms and how the diagnosis is made
The typical presentation is pain and tenderness over the base of the affected finger on the palm side, often with a palpable nodule, plus a catching or popping sensation with finger movement. Symptoms are frequently worse in the morning and improve somewhat with use through the day. As the condition progresses, catching can become locking — the finger becomes stuck in a bent position and needs to be pulled straight, sometimes painfully, with the other hand. In severe, longstanding cases the finger may become fixed in flexion and no longer able to be straightened at all.
Trigger finger is almost always a clinical diagnosis. A focused history plus examination — palpating for a tender nodule at the A1 pulley and observing or feeling the tendon catch during active finger flexion and extension — is usually sufficient, and imaging is not routinely needed. Ultrasound can be useful in atypical or diagnostically uncertain cases, showing tendon thickening, sheath fluid, or A1 pulley thickening, and is increasingly used to guide injections precisely, but it is not required to start standard treatment.
| Grade | Clinical presentation |
|---|---|
| Mild | Pain and tenderness over the A1 pulley, no catching |
| Moderate | Catching or clicking with active finger motion, no locking |
| Severe | Finger locks in flexion; can be straightened passively |
| Fixed | Finger locked in flexion; cannot be straightened even passively |
A few other conditions can mimic trigger finger and are worth distinguishing: Dupuytren's contracture (a palm cord that limits finger extension but does not typically produce catching), flexor tendon tumours or ganglions, and, less commonly, a locked metacarpophalangeal joint from arthritis. The presence of a tender, mobile nodule at the base of the finger that moves with tendon excursion is the most distinguishing clinical feature of true trigger finger.
What the evidence says about treatment
Management is typically staged, starting with the least invasive options and reserving surgery for cases that don't respond to conservative care. Mild, early cases — particularly of short duration — have a reasonable chance of resolving with observation and activity modification alone, but most symptomatic cases that come to clinical attention benefit from active treatment.
Commonly used treatment options
- Activity modification and NSAIDs — a reasonable first step for mild, recent-onset symptoms
- Splinting — a splint that blocks motion at the metacarpophalangeal joint, worn for several weeks to months, reduces repetitive tendon excursion through the pulley
- Corticosteroid injection — an injection of corticosteroid into the flexor tendon sheath at the A1 pulley; the most widely used and best-studied non-surgical treatment
- Combining splinting with injection — some evidence suggests this may improve and stabilise results compared with injection alone
- Percutaneous release — a minimally invasive needle-based release of the A1 pulley, performed under local anaesthetic, often ultrasound-guided
- Open surgical release — a small incision over the A1 pulley to divide it directly under vision; the traditional surgical standard, reserved for cases that fail non-surgical treatment
What the evidence shows — corticosteroid injection: A meta-analysis of randomised controlled trials found the pooled successful-treatment rate with corticosteroid injection was approximately 64%, compared with approximately 28% for control injections, with a pooled relative risk of treatment failure of 0.49 favouring corticosteroid (95% CI 0.40–0.60), and only mild or no complications reported across the included trials (Pathak et al., Journal of Hand Surgery [Asian-Pacific Volume], 2022). This is consistent with corticosteroid injection's position as the standard first-line active treatment once conservative measures alone have not resolved symptoms — though a meaningful minority of patients, particularly those with diabetes or longstanding, higher-grade disease, do not achieve lasting relief from injection and go on to need a second injection or surgery.
What the evidence shows — adding a splint: A randomised controlled trial comparing corticosteroid injection alone with corticosteroid injection plus a three-month static metacarpophalangeal-blocking splint in 60 patients found both approaches improved symptoms, but the splint group showed greater reductions in pain and symptom severity, with more stable improvement over the follow-up period (Tajik et al., Musculoskeletal Care, 2022). This suggests splinting may be a useful, low-risk adjunct to injection for patients willing to tolerate several months of MCP-joint immobilisation, though it is not yet established as a universal standard of care.
When injection (with or without splinting) fails to provide durable relief — generally after one or two attempts — surgical release of the A1 pulley is highly effective and is considered the definitive treatment, with reported success rates generally exceeding 90%.
What the evidence shows — percutaneous vs. open release: A randomised controlled trial comparing ultrasound-guided percutaneous release with open surgical release found both techniques produced significant, comparable improvements in pain and function at 12 months, with no significant difference in complication or revision rates between groups, though the percutaneous group showed faster early functional recovery and, at one-year follow-up, significantly greater grip strength (Öner et al., Journal of Clinical Medicine, 2025). Percutaneous release is minimally invasive and avoids a formal incision, but carries a small, specific risk of incomplete release or, rarely, injury to the adjacent digital nerve — which is why it is usually performed by a surgeon experienced in the technique, often with ultrasound guidance.
Recovery after surgical release
Both percutaneous and open release are typically outpatient procedures done under local anaesthetic. Finger motion is generally encouraged from the first day to prevent stiffness, and most patients resume light daily activities within days to about two weeks, with full recovery of grip strength and comfort over four to six weeks. Persistent or recurrent triggering after a technically adequate release is uncommon but can occur, particularly in patients with diabetes or involvement of multiple fingers.
When to see a specialist
A finger that occasionally clicks without pain can often be watched. Evaluation is worthwhile when there is persistent pain at the base of the finger, when the finger catches or locks with movement, or when a finger becomes stuck and needs to be straightened by hand. Because diabetes is such a strong and modifiable-adjacent risk factor, a new diagnosis of trigger finger — especially if it affects more than one finger — is also a reasonable prompt to check blood glucose if this hasn't been done recently. A hand surgeon, orthopaedic surgeon, or primary care physician can confirm the diagnosis, rule out the mimics described above, and guide a staged treatment plan starting with the least invasive appropriate option.
References (PubMed / Journal)
Pathak SK, Salunke AA, Menon PH, Thivari P, Nandy K, Yongsheng C. Corticosteroid Injection for the Treatment of Trigger Finger: A Meta-Analysis of Randomised Control Trials. J Hand Surg Asian Pac Vol. 2022;27(1):89-97. DOI: 10.1142/S242483552250014X
Löfgren JP, Zimmerman M, Dahlin LB, Nilsson PM, Rydberg M. Diabetes Mellitus as a Risk Factor for Trigger Finger – a Longitudinal Cohort Study Over More Than 20 Years. Front Clin Diabetes Healthc. 2021;2:708721. DOI: 10.3389/fcdhc.2021.708721
Tajik H, Shirzad N, Rahimibarghani S, Rezapour B, Nejadhosseinian M, Faezi ST, Fateh HR. The effects of adding splint use to corticosteroid injection for the treatment of trigger finger: A randomized controlled trial. Musculoskeletal Care. 2022;20(4):908-916. DOI: 10.1002/msc.1647
Öner SK, Demirkiran ND, Dulgeroglu TC, et al. Ultrasound-Guided Percutaneous Versus Open A1 Pulley Release for Trigger Finger: A Randomized Controlled Trial. J Clin Med. 2025;14(19):7064. DOI: 10.3390/jcm14197064